Dimeric DOTA-α-melanocyte-stimulating hormone analogs: Synthesis and in vivo characteristics of radiopeptides with high in vitro activity

Journal of Receptors and Signal Transduction

Volumn 27, Issue 5-6, 2007, Pages 383-409

  Bapst, Jean Philippe ^a   Froidevaux, Sylvie ^a   Calame, Martine ^a   Tanner, Heidi ^a   Eberle, Alex N ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

MSH; Dimeric peptide; DOTA; MC1 R; Melanoma; Tumor targeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERMEDIN DERIVATIVE; INDIUM 111; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIMERIZATION; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING;

ALPHA-MSH; ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; DIMERIZATION; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MELANOMA, EXPERIMENTAL; MICE; OLIGOPEPTIDES; RADIOLIGAND ASSAY; TISSUE DISTRIBUTION;

EID: 37549055830     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890701723528     Document Type: Article

References (75)

1. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995, 36, 1825-1835.
2. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004, 5, 292-302.
3. Eberle AN, Mild G, Froidevaux S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: Application to somatostatin receptor-expressing tumors. J Recept Signal Transduct 2004, 24, 319-455.
4. Mariani G, Erba PA, Signore A. Receptor-mediated tumor targeting with radiolabeled peptides: There is more to it than somatostatin analogs. J Nucl Med 2006, 47, 1904-1906.
5. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: State of science. J Nucl Med 2003, 44, 1945-1961.
6. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004, 80(Suppl 1), 51-56.
7. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005, 46(Suppl 1), 67S-75S
8. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002, 66, 161-183.
9. Otte A, Hermann R, Heppeler A, Behe M, Jermann E, Powell P, Mäcke HR, Müller J. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999, 26, 439-447.
10. 90Y-DOTATOC. Eur J Nucl Med 2001, 28, 1552-1554.
11. Lambert B, Cybulla M, Weiner SM, van de Wiele C, Ham H, Dierckx RA, Otte A. Renal toxicity after radionuclide therapy. Radiat Res 2004, 161, 607-611.
12. Froidevaux S, Heppeler A, Eberle AN, Meier AM, Häusler M, Beglinger C, Behe M, Powell P, Mäcke HR. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000, 141, 3304-3312.
13. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996, 37, 829-833.
14. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Mäcke HR, de Jong M. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997, 24, 761-769.
15. 90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imag 2004, 31, 1038-1046.
16. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005, 23, 2754-2762.
17. 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors? Nat Clin Pract Endocrinol Metab 2005, 1, 20-21.
18. 3]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imag 2006, 33, 1346-1351.
19. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney. Eur J Nucl Med 2001, 28, 1447-1449.
20. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998, 25, 201-212.
21. Eberle AN. The Melanotropins: Chemistry, Physiology and Mechanisms of Action. Basel, Karger, 1988, 1-556.
22. Eberle AN. Proopiomelanocortin and the melanocortin peptides. In: Cone RD, ed. The Melanocortin Receptors. Totowa, NJ, Humana Press, 2000, 3-67.
23. Eberle AN, Froidevaux S, Siegrist W. Melanocortins and melanoma. In: Cone RD, ed. The Melanocortin Receptors. Totowa, NJ, Humana Press, 2000, 491-520.
24. Eves PC, MacNeil S, Haycock JW. α-Melanocyte-stimulating hormone, inflammation and human melanoma. Peptides 2006, 27, 444-452.
25. Abdel-Malek Z, Scott MC, Suzuki I, Tada A, Im S, Lamoreux L, Ito S, Barsh G, Hearing VJ. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res 2000, 13(Suppl 8), 156-162.
26. Hadley ME, Sharma SD, Hruby VJ, Levine N, Dorr RT. Melanotropic peptides for therapeutic and cosmetic tanning of the skin. Ann NY Acad Sci 1993, 680, 424-439.
27. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dematol 2004, 140, 827-835.
28. De Luca M, Siegrist W, Bondanza S, Mathor M, Cancedda R, Eberle AN. α-Melanocyte stimulating hormone (α-MSH) stimulates normal human melanocyte growth by binding to high-affinity receptors. J Cell Sci 1993, 105, 1079-1084.
29. Siegrist W, Solca F, Stutz S, Giuffrè L, Carrel S, Girard J, Eberle AN. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989, 49, 6352-6358.
30. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for α-melanocyte-stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int J Cancer 1988, 41, 248-255.
31. Siegrist W, Stutz S, Eberle AN. Homologous and heterologous regulation of α-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res 1994, 54, 2604-2610.
32. Bagutti C, Oestreicher M, Siegrist W, Oberholzer M, Eberle AN. α-MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. J Recept Signal Transduct Res 1995, 15, 427-442.
33. Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp Dermatol 1996, 5, 325-333.
34. Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, Serrano A, Korenblit C, Petersson M, Chhajlani V, Larsson O, Kiessling R. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 2002, 87, 414-422.
35. 111In]-DTPA-labeled analogues of α-MSH for the detection of MSH receptors in vitro and in vivo. Ann NY Acad Sci 1993, 680, 445-447.
36. 111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo. Int J Cancer 1994, 58, 749-755.
37. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-a-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002, 43, 1699-1706.
38. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004, 45, 116-123.
39. Eberle AN, Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: From tritium to indium. J Mol Recognit 2003, 16, 248-254.
40. 111In-DOTA-rhenium cyclized α-MSH analog: A novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med 2001, 42, 1847-1855.
41. 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem 2002, 45, 3048-3056.
42. 188Re-labeled α-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002, 101, 480-487.
43. Cheng Z, Chen J, Quinn TP, Jurisson SS. Radioiodination of rhenium cyclized α-melanocyte stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 2004, 64, 1411-1418.
44. 177Lu labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 2005, 32, 485-493.
45. 177Lu labeled α-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 2006, 33, 723-733.
46. Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis JS. Synthesis and biological evaluation of Cu-64 labeled rhenium-cyclized α-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007, 48, 64-72.
47. 18F-labeled α-melanocyte-stimulating hormone analog. J Nucl Med 2007, 48, 987-994.
48. 64Cu- labeled α-melanocyte-stimulating hormone analog for microPET imaging of melanocortin-1 receptor expression. Bioconjug Chem 2007, 18, 765-772.
49. Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: Structural parameters affecting tumor uptake nd kidney uptake. J Nucl Med 2005, 46, 887-895.
50. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980, 77, 5754-5758.
51. Eberle AN. The Melanotropins: Chemistry, Physiology and Mechanisms of Action. Basel, Karger, 1988, 344-345.
52. Al-Obeidi F, Hruby VJ, Hadley ME, Sawyer TK, Castrucci AM. Design, synthesis, and biological activities of a potent and selective α-melanotropin antagonist. Int J Pept Protein Res 1990, 35, 228-234.
53. Muceniece R, Mutule I, Mutulis F, Prusis P, Szardenings M, Wikberg JE. Detection of regions in the MC1 receptor of importance for the selectivity of the MC1 receptor super-selective MS04/MS05 peptides. Biochim Biophys Acta 2001, 1544, 278-282.
54. Sawyer TK, Hruby VJ, Darman PS, Hadley ME. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980, 77, 5754-5758.
55. Hadley ME, Hruby VJ, Blanchard J, Dorr RT, Levine N, Dawson BV, Al-Obeidi F, Sawyer TK. Discovery and development of novel melanogenic drugs. Melanotan-I and II. Pharm Biotechnol 1998, 11, 575-595.
56. Giblin MF, Jurisson SS, Quinn TP. Synthesis and characterization of rhenium-complexed α-melanotropin analogs. Bioconjug Chem 1997, 8, 347-353.
57. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of α-melanotropin petpide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998, 95, 12814-12818.
58. Eberle AN, Kriwaczek VM, Schwyzer R. Hormone-receptor interactions: Melanotropin activities of covalent serum albumin complexes with α-melanotropin, α-melanotropin fragments and enkephalin. FEBS Lett 1977, 80, 246-250.
59. Eberle AN, Kriwaczek VM, Schwyzer R. Studies on tyrosinase stimulation, binding and degradation of α-MSH interacting with non-synchronized mouse melanoma cells in culture. In: Gross E, Meienhofer J, eds. Peptides, Structure and Biological Function. Rockford, IL, Pierce Chemical Corp, 1979, 1033-1036.
60. Kriwaczek VM, Eberle AN, Müller M, Schwyzer R. Tobacco mosaic virus as a carrier for small molecules. I. The preparation and characterization of a TMV/α-melanotropin conjugate. Helv Chim Acta 1978, 61, 1232-1240.
61. Eberle AN. Studies on melanotropin (MSH) receptors of melanophores and melanoma cells. Biochem Soc Trans 1981, 129, 113-116.
62. Feuilloley M, Stolz MB, Delarue C, Fauchère J-L, Vaudry H. Structure-activity relationships of monomeric and dimeric synthetic ACTH fragments in perifused frog adrenal slices. J Steroid Biochem 1990, 35, 583-592.
63. Vagner J, Handl HL, Gillies RJ, Hruby VJ. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of α-MSH. Bioorg Med Chem Lett 2004, 14, 211-215.
64. Atherton E, Sheppard RC. Solid Phase Synthesis: a Practical Approach. Oxford, IRL Press, 1989.
65. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973, 242, 148-149.
66. Froidevaux S, Eberle AN. Homologous regulation of melanocortin-1 receptor (MC1R) expression in melanoma tumor cells in vivo. J Recept Signal Transduct Res 2002, 22, 111-121.
67. Siegrist W, Eberle AN. In situ melanin assay for MSH using mouse B16 melanoma cells in culture. Anal Biochem 1986, 159, 191-197,
68. 11), a cyclized peptide analogue of α-MSH. J Med Chem 2005, 48, 2985-2992.
69. 111In labeled α-melanocyte stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 2007, 48, 73-80.
70. 188Re labeled α-melanocyte stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005, 46, 121-129.
71. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, Fritzberg AR, Winkelmann CT, Hoffman TJ, Quinn TP. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res 2005, 11, 5616-5621.
72. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets 2004, 8, 565-586.
73. Yang H, Weiyuan JK. Dendrimers for pharmaceutical and biomedical applications. J Biomater Sci Polymer Edn 2006, 17, 3-19.
74. Svenson S, Tomalia DA. Dendrimers in biomedical applications - Reflections on the field. Adv Drug Delivery Rev 2005, 57, 2106-2129.
75. Sadler K, Tam JP. Peptide dendrimers: applications and synthesis. Rev Mol Biotechnol 2002, 90, 195-229.